{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:03:30Z","timestamp":1789470210052,"version":"build-2803163510"},"reference-count":44,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2026.2183","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:43:43Z","timestamp":1785915823000},"page":"1-13","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic and therapeutic importance of TROP\u20112 and MUC\u20111 in non\u2011small cell lung cancer: A systematic review and meta\u2011analysis"],"prefix":"10.3892","volume":"25","author":[{"given":"Pimwouth","family":"Natisoontorn","sequence":"first","affiliation":[{"name":"Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiratt","family":"Lumpaopong","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nutnicha","family":"Sorachaimetha","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodchanan","family":"Singhanat","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rungdawan","family":"Wongsamart","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peti","family":"Thuwajit","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roongnapa","family":"Khampang","sequence":"additional","affiliation":[{"name":"Siriraj Health Policy Unit, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanitra","family":"Thuwajit","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"key20260915130951_b1-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"key20260915130951_b2-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: A heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"key20260915130951_b3-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.pdpdt.2018.03.006","article-title":"A review of nanoparticle photosensitizer drug delivery uptake systems for photodynamic treatment of lung cancer","volume":"22","author":"Mokwena","year":"2018","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"e32899","key":"key20260915130951_b4-BR-25-4-02183","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032899","article-title":"Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment","volume":"102","author":"Alduais","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"key20260915130951_b5-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1158\/1078-0432.CCR-19-2300","article-title":"Integrating immunotherapy and targeted therapy in cancer treatment: Mechanistic insights and clinical implications","volume":"26","author":"Bergholz","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20260915130951_b6-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/curroncol31010001","article-title":"Overcoming resistance mechanisms to immune checkpoint inhibitors: Leveraging the anti-tumor immune response","volume":"31","author":"Coschi","year":"2023","journal-title":"Curr Oncol"},{"key":"key20260915130951_b7-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"9019","DOI":"10.3390\/cimb45110566","article-title":"Advances in CAR T cell therapy for non-small cell lung cancer","volume":"45","author":"Ma","year":"2023","journal-title":"Curr Issues Mol Biol"},{"key":"key20260915130951_b8-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"issue":"6567","key":"key20260915130951_b9-BR-25-4-02183","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126567","article-title":"MUC1: Structure, function, and clinic application in epithelial cancers","volume":"22","author":"Chen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20260915130951_b10-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bbrc.2019.06.003","article-title":"Induction of Trop-2 expression through the binding of galectin-3 to MUC1","volume":"516","author":"Yamashita","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"key20260915130951_b11-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","article-title":"TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer","volume":"30","author":"Bessede","year":"2024","journal-title":"Clin Cancer Res"},{"key":"key20260915130951_b12-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.7150\/jca.57711","article-title":"Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment","volume":"12","author":"Sun","year":"2021","journal-title":"J Cancer"},{"key":"key20260915130951_b13-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/pin.12911","article-title":"Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation","volume":"70","author":"Mito","year":"2020","journal-title":"Pathol Int"},{"issue":"4181658","key":"key20260915130951_b14-BR-25-4-02183","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4181658","article-title":"Expression of mucin family proteins in non-small-cell lung cancer and its role in evaluation of prognosis","volume":"2022","author":"Tu","year":"2022","journal-title":"J Oncol"},{"key":"key20260915130951_b15-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jtho.2023.10.017","article-title":"MUC1-C is a common driver of acquired osimertinib resistance in NSCLC","volume":"19","author":"Haratake","year":"2024","journal-title":"J Thorac Oncol"},{"key":"key20260915130951_b16-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5146\/tjpath.2022.01593","article-title":"Evaluation of MUC1, MUC2, MUC5AC, and MUC6 expression differences in lung adenocarcinoma subtypes by using a final immunoreactivity score (FIRS)","volume":"39","author":"Buyuk","year":"2023","journal-title":"Turk Patoloji Derg"},{"issue":"702491","key":"key20260915130951_b17-BR-25-4-02183","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.702491","article-title":"YBX1 enhances metastasis and stemness by transcriptionally regulating MUC1 in lung adenocarcinoma","volume":"11","author":"Xie","year":"2021","journal-title":"Front Oncol"},{"issue":"249","key":"key20260915130951_b18-BR-25-4-02183","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01741-5","article-title":"Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C\/PD-L1 axis","volume":"39","author":"Jiang","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"key20260915130951_b19-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1590\/1806-9282.20210259","article-title":"Prognostic assessment of tumor markers in lung carcinomas","volume":"68","author":"Bes-Scartezini","year":"2022","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"202","key":"key20260915130951_b20-BR-25-4-02183","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12463","article-title":"A novel Tn antigen epitope-recognizing antibody for MUC1 predicts clinical outcome in patients with primary lung adenocarcinoma","volume":"21","author":"Kato","year":"2021","journal-title":"Oncol Lett"},{"issue":"e151418","key":"key20260915130951_b21-BR-25-4-02183","article-title":"Predictive molecular blood biomarkers in non-small cell lung cancer","volume":"7","author":"Mohamadnia","year":"2022","journal-title":"J Cell Mol Anesth"},{"issue":"323","key":"key20260915130951_b22-BR-25-4-02183","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020323","article-title":"Preferential localization of MUC1 glycoprotein in exosomes secreted by non-small cell lung carcinoma cells","volume":"20","author":"Pan","year":"2019","journal-title":"Int J Mol Sci"},{"key":"key20260915130951_b23-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.4161\/cbt.26341","article-title":"Chemotherapy agents-induced immunoresistance in lung cancer cells could be reversed by trop-2 inhibition in vitro and in vivo by interaction with MAPK signaling pathway","volume":"14","author":"Wang","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"key20260915130951_b24-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cell.2009.01.039","article-title":"A mutant-p53\/Smad complex opposes p63 to empower TGFbeta-induced metastasis","volume":"137","author":"Adorno","year":"2009","journal-title":"Cell"},{"key":"key20260915130951_b25-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"213","DOI":"10.15430\/JCP.2020.25.4.213","article-title":"Recent advances in the development of TGF-\u03b2 signaling inhibitors for anticancer therapy","volume":"25","author":"Lee","year":"2020","journal-title":"J Cancer Prev"},{"key":"key20260915130951_b26-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1038\/onc.2017.47","article-title":"MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer","volume":"36","author":"Bouillez","year":"2017","journal-title":"Oncogene"},{"key":"key20260915130951_b27-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/onc.2012.158","article-title":"MUC1-C oncoprotein as a target in breast cancer: Activation of signaling pathways and therapeutic approaches","volume":"32","author":"Kufe","year":"2013","journal-title":"Oncogene"},{"key":"key20260915130951_b28-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"20686","DOI":"10.1074\/jbc.M202104200","article-title":"The macrophage C-type lectin specific for galactose\/N-acetylgalactosamine is an endocytic receptor expressed on monocyte-derived immature dendritic cells","volume":"277","author":"Higashi","year":"2002","journal-title":"J Biol Chem"},{"key":"key20260915130951_b29-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/prca.201300024","article-title":"Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers","volume":"7","author":"Ju","year":"2013","journal-title":"Proteomics Clin Appl"},{"key":"key20260915130951_b30-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"8358","DOI":"10.1158\/0008-5472.CAN-07-1035","article-title":"Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells","volume":"67","author":"Napoletano","year":"2007","journal-title":"Cancer Res"},{"key":"key20260915130951_b31-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"20866","DOI":"10.1074\/jbc.M112.357293","article-title":"The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function","volume":"287","author":"Ahmad","year":"2012","journal-title":"J Biol Chem"},{"issue":"4805","key":"key20260915130951_b32-BR-25-4-02183","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194805","article-title":"Emergence of MUC1 in mammals for adaptation of barrier epithelia","volume":"14","author":"Kufe","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20260915130951_b33-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20260915130951_b34-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus. docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol"},{"issue":"162","key":"key20260915130951_b35-BR-25-4-02183","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"Araghi","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"e1284722","key":"key20260915130951_b36-BR-25-4-02183","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1284722","article-title":"PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells","volume":"6","author":"Wei","year":"2017","journal-title":"Oncoimmunology"},{"key":"key20260915130951_b37-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"key20260915130951_b38-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"key20260915130951_b39-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"key20260915130951_b40-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"key20260915130951_b41-BR-25-4-02183","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-014-0151-3","article-title":"Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines","volume":"15","author":"Lam","year":"2015","journal-title":"Cancer Cell Int"},{"key":"key20260915130951_b42-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"93825","DOI":"10.18632\/oncotarget.21225","article-title":"Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"key20260915130951_b43-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.21037\/tcr-23-956","article-title":"Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: A narrative review","volume":"12","author":"Zhang","year":"2023","journal-title":"Transl Cancer Res"},{"key":"key20260915130951_b44-BR-25-4-02183","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/2211-5463.13088","article-title":"Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"FEBS Open Bio"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:09:56Z","timestamp":1789466996000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2026.2183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,5]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2026.2183","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]}}}